ScholarIQanswers from OpenAlex
Fondazione Michelangelo
InstitutionResearch output, impact & collaborations
Fondazione Michelangelo is a institution indexed in ScholarIQ from OpenAlex.
What is known about Fondazione Michelangelo?
ScholarIQrecord summary
Fondazione Michelangelo is a research organisation in Milan, IT. OpenAlex records 155 works and 21,207 citations for it.
How many works does Fondazione Michelangelo have?
ScholarIQindexed works
Fondazione Michelangelo has 155 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Fondazione Michelangelo have?
ScholarIQcitation count
Fondazione Michelangelo has 21,207 citations in the OpenAlex counts ScholarIQ stores.
What is the average h-index at Fondazione Michelangelo?
ScholarIQavg h-index
Fondazione Michelangelo has an average h-index of 87 in OpenAlex.
What is the ROR of Fondazione Michelangelo?
ScholarIQror
The ROR for Fondazione Michelangelo is on the source record.
What is the OpenAlex record for Fondazione Michelangelo?
ScholarIQopenalex
The OpenAlex for Fondazione Michelangelo is on the source record.
Who are the most-cited researchers behind Fondazione Michelangelo?
ScholarIQtop researchers by citations
What are the most-cited papers on Fondazione Michelangelo?
ScholarIQmost cited works
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Martine Piccart, Marion Procter, Brian Leyland‐Jones, Aron Goldhirsch, Michael Untch, Ian Smith, Luca Gianni, José Baselga, Richard H. Bell, Christian Jackisch, David Cameron, Mitch Dowsett, Carlos H. Barrios, Günther Steger, Chiun‐Sheng Huang, Michael Andersson, Moshe Inbar, Mikhail Lichinitser, István Láng, Ulrike Nitz, Hiroji Iwata, Christoph Thomssen, Caroline Lohrisch, Thomas Suter, Josef Rüschoff, Tamás Sütö, Victoria Greatorex, Carol Ward, Carolyn Straehle, Eleanor McFadden, Mirko Dolci, Richard D. Gelber
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P. Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa, Sandra M. Swain, Tatiana M. Prowell, Sibylle Loibl, D. Lawrence Wickerham, Jan Bogaerts, José Baselga, Charles M. Perou, Gideon M. Blumenthal, Jens‐Uwe Blohmer, Eleftherios P. Mamounas, Jonas Bergh, Semiglazov Vf, Robert Justice, Holger Eidtmann, Soonmyung Paik, Martine Piccart, Rajeshwari Sridhara, Peter A. Fasching, Leen Slaets, Shenghui Tang, Bernd Gerber, Charles E. Geyer, Richard Pazdur, Nina Ditsch, Priya Rastogi, W. Eiermann, Gϋnter von Minckwitz
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar Sardesai, Kevin Kalinsky, Amelia Zelnak, Robert Weaver, Tiffany A. Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab, Javier Cortés, Joyce O’Shaughnessy, Véronique Dièras, Cristiano Ferrario, Peter Schmid, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Hope S. Rugo
Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer
Gianni Bonadonna, Ercole Brusamolino, Pinuccia Valagussa, Anna Rossi, Luisa Brugnatelli, Cristina Brambilla, Mario De Lena, Gabriele Tancini, Emilio Bajetta, R Musumeci, Umberto Veronesi
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni, W. Eiermann, Semiglazov Vf, Alexey Manikhas, Aňa Lluch, S. Tjulandin, Milvia Zambetti, Federico Vázquez, Mikhail Byakhow, Mikhail Lichinitser, Miguel Ángel Climent, Eva Ciruelos, B. Ojeda, Mauro Mansutti, А. А. Божок, Roberta Baronio, A. Feyereislova, Claire Barton, Pinuccia Valagussa, José Baselga
How much of the research on Fondazione Michelangelo is open access?
ScholarIQopen access share
58%OPEN ACCESS